 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Raltegravir (MK-0518, Isentress)
Overview
- A Clinical Overview of Raltegravir (MK-0518, Isentress) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Comparing Two Integrase Inhibitors (September/October 2008)
A guide geared for patients.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - Prescribing Information for Raltegravir (MK-0518, Isentress) (PDF) (May 2008)
From Merck & Co., Inc. - Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo - Adverse Effects of Antiretroviral Drugs: Integrase Inhibitors (November 2007)
A table summarizing the most common and most serious adverse events associated with integrase inhibitors.
From HIV InSite Knowledge Base Chapter - The Impact of Raltegravir: The Body PRO Interviews David Wohl, M.D. (October 23, 2007)
From The Body PRO - Mixed Reaction to Raltegravir Pricing: Project Inform (October 15, 2007)
From Project Inform - Raltegravir, First-in-Class HIV Integrase Inhibitor, Wins U.S. Approval (October 12, 2007)
From U.S. Food and Drug Administration - Drugs in Development for Treatment-Naive Patients (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - The Bottom Line on Darunavir, Etravirine, Raltegravir, Maraviroc (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - MK-0518 (Raltegravir) in Treatment-Naive Patients (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Research
- ICAAC 2007 Study Summaries: An Interview With Joseph Eron, M.D. (September 20, 2007)
Dr. Eron discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced patients. .
From The Body PRO - Briefing Document (Background Package): Raltegravir (PDF) (September 5, 2007)
FDA Antiviral Drugs Advisory Committee Meeting.
From U.S. Food and Drug Administration - Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - FDA Grants Priority Review Status to Merck's Antiretroviral Raltegravir (June 29, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - 77% of Treatment-Experienced Patients on MK-0518 (raltegravir) Plus OBT Achieve Viral Load of Less Than 400 Copies: A Study Summary From David Cooper, M.D., and Roy Steigbigel, Ph.D. (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - 79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - The Integrase Inhibitor MK-0518 Demonstrates a Favorable Lipid Profile (September 27, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - EARMRK: Expanded Access Research Program for MK-0518 (August 17, 2006)
From Merck & Co., Inc. - Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options (August 17, 2006)
Worldwide access program will be conducted along with phase III studies.
To read PDF, click here
From Merck & Co., Inc. - Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients (August 17, 2006)
In XVI International AIDS Conference - Integrase Inhibitors: The Next Wave? (Spring 2006)
A quick look at MK-518 and GS-9137.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
  |
  |